Main Menu

Doc Refuses To Sell Leukemia Med To Big Pharma

Doc Refuses To Sell Leukemia Med To Big Pharma

Matt Weeks | September 1, 2019

In a rare and important move, the U.S. Food and Drug Administration has recently granted special, preliminary approval to a cannabis-based drug being used to treat several blood cancer types.

Chrysoeriol, a new drug that has shown promise in combatting acute myeloid leukemia (AML), has been granted approval under the FDA’s Orphan Drug Act. The law, passed in 1983, allows expedited approval for drugs that treat rare diseases, such as Huntington’s Disease, Muscular Dystrophy, and ALS.

The special designation does not mean the US can manufacture and sell the drug. Rather, it allows its maker certain tax breaks and benefits in order to get the drug to market.

This is a very big deal.

Doc Refuses To Sell Leukemia Med To Big Pharma






Comments are Closed